Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT07540442Phase 3Not yet recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing MG-K10 with Placebo (2 arms). Primary endpoints: Eczema Area and Severity Index 75% reduction at 16 weeks and Investigator's Global Assessment score of 0 or 1 at 16 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
comekibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07540442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540442.